Streetbeat News

Stock Prices

ZBH

Zimmer Biomet Holdings (NYSE:ZBH) has received mixed analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for ZBH has increased by 5.57% to $134.29. Analyst actions include rating adjustments and price target changes, reflecting dynamic market conditions and company performance. Zimmer Biomet, a leader in orthopedic reconstructive implants, has shown a revenue growth of 6.3% but lags behind industry peers. Its net margin outperforms industry averages, yet its ROE is below benchmarks.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm

COTY

Coty's stock price declined following Ulta Beauty's report of weak guidance during a conference, indicating potential concerns in the beauty sector.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 4:59 pm

ABUS

MRNA

Arbutus Biopharma's stock is trading higher due to the circulation of documents related to a patent infringement lawsuit between Arbutus/Genevant and Moderna.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 4:57 pm

ACHR

JOBY

Archer Aviation Inc (NYSE:ACHR) is planning to launch its electric air-taxi service in the UAE by the end of 2025, aiming to compete with Joby Aviation Inc (NYSE:JOBY) in the regional commuter service market. CEO Adam Goldstein announced plans for operations in Abu Dhabi and Dubai, with regulatory assurances in place. The company recently completed significant battery pack drop testing, advancing its Midnight aircraft's development. ACHR shares rose 4.13% to $4.509.

Portfolio Pulse from Shivani Kumaresan

April 03, 2024 | 4:57 pm

SNDX

During a live CNBC appearance, StemPoint Capital's CIO Michelle Ross mentioned Syndax Pharmaceuticals, which led to a spike in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 4:52 pm

NRG

NRG Energy announced it will repurchase approximately $251 million of its 2.75% convertible senior notes due 2048, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 4:51 pm

CVS

Recent options trading activity for CVS Health (NYSE:CVS) indicates a mixed market sentiment, with an equal split between bullish and bearish positions. Notable trades include both puts and calls, with a focus on strike prices between $72.5 and $80.0. The trading volume and open interest analysis suggest significant interest in these price ranges. CVS Health's current market standing shows a slight increase in stock price to $74.03, with neutral RSI indicators and an upcoming earnings announcement. Analyst opinions vary, with an average price target of $86.0, reflecting differing views on the company's future performance.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 4:46 pm

CCJ

Smart money investors have shown a significant bullish interest in Cameco (NYSE:CCJ) options, with a notable volume of trades indicating a target price range of $33.0 to $55.0. The analysis of options trades over the last 3 months reveals a 60% bullish and 40% bearish sentiment among big-money traders. Significant trades include bullish calls with strike prices ranging from $46.00 to $50.00. Cameco, a major uranium producer, has seen its stock price slightly increase by 0.25% to $47.8, with analysts from Goldman Sachs setting a target price of $55.0.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 4:46 pm

ANF

Abercrombie & Fitch (NYSE:ANF) has seen a mix of bullish and bearish options trading, with a slight majority being bullish. The trading volume and open interest suggest a price target range of $108.0 to $155.0. The company's stock is currently trading at $131.0, with neutral RSI indicators and an earnings announcement expected in 49 days. Analysts have varying opinions, with target prices ranging from $103 to $155.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 4:45 pm

CRNX

During CNBC's Halftime segment 'Opportunities In Biotech', Michelle Ross highlighted Crinetics Pharmaceuticals (CRNX) as her top biotech pick, labeling it a GLP-1 adjacent play.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 4:40 pm